SNU-5 In Vitro Anti-Tumor Efficacy Assay

This assay is to provide SNU-5-based In Vitro Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vitro Anti-Tumor Efficacy Assay

SNU-5-cell based In Vitro Anti-Tumor Efficacy Assay

Tumor-derived cell lines have been the mainstay for anti-cancer drug discovery, and the assessment of in vitro efficacy is a common method to evaluate the anti-cancer efficacy with various kinds of therapeutic candidates.

Oncology Efficacy Assays